• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Adding Fabrication Capabilities: Additive Manufacturing for Production Parts

    Delivering the Goods: The Evolving World of Combination Products

    Anxious Undertones: The 2019 Year in Review

    From Art to Science: The Changing Face of Extrusion

    Exact Science: A Micromolding Roundtable
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    15-Year Tele-Critical Care Collabration Yields Significant ICU Improvement Results

    Prellis Biologics' New Tool Simplifies Complex Tissue Engineering

    InspireMD's CEO Steps Down

    Celmatix Sues Research Partner 23andMe for $100M

    FDA Cleared New Cochlear Osia 2 System
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Adding Fabrication Capabilities: Additive Manufacturing for Production Parts

    Delivering the Goods: The Evolving World of Combination Products

    Anxious Undertones: The 2019 Year in Review

    From Art to Science: The Changing Face of Extrusion

    Exact Science: A Micromolding Roundtable
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    From Genome Sequencing to the World’s First Portable MRI

    An Update on Digital Health

    ‘If You’re Reading This, You Need to Be at This Meeting’

    Five Steps for Succeeding Globally in Medtech

    Unlocking Market Doors with Real-World Evidence
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Carclo Technical Plastics

    Pulse Systems

    RJG Inc.

    MicroLumen Inc.

    Nelson Laboratories LLC
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    EU's MDR: Irresistible Force Meets Immovable Object

    Ladies First: An Examination of the Women's Health Device Industry

    Localizing Medical Devices

    Sounding Board: Looking Back at 2019 and Gazing at 2020

    Understanding Key Processes for Mixing APIs with Silicone
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    DELMIAWORKS (IQMS)

    GS Plastic Optics

    Accumold

    Nelson Laboratories LLC

    NN Life Sciences/Paragon Medical
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    Sequana Medical Announces Unconditional FDA IDE Approval to Start alfapump Pivotal Study

    alfapump pivotal study will examine the treatment of recurrent or refractory ascites due to liver cirrhosis.

    Related CONTENT
    • Latest Steps to Strengthen FDA’s 510(k) Program for Premarket Review
    • Electrifying Healthcare: A Look at Electronics Manufacturing Services for Medtech
    • Venclose, Viant Partner To Deliver Vein Treatment Solutions
    • Electrophysiology Expert Joins BioSig Technologies Management Team
    • Accomplished Healthcare Researcher Joins MedX Health's Medical Advisory Board
    Globe Newswire07.19.19
    Sequana Medical NV, a commercial stage medical device company focused on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, said the U.S. Food and Drug Administration (FDA) has unconditionally approved its Investigational Device Exemption (IDE) application for POSEIDON, the alfapump pivotal study in patients with recurrent or refractory ascites due to liver cirrhosis. The study is intended to support approval and reimbursement of the alfapump in the United States and Canada.
     
    “We are delighted with the IDE approval and optimised clinical trial design for POSEIDON and are grateful for the close collaboration with the FDA. As a result, and together with the Breakthrough Device Designation granted in January this year, we have brought forward our plans for U.S. launch of the alfapump to H1 2022,” said Ian Crosbie, CEO of Sequana Medical. “This is good news for patients as the growing prevalence of cirrhosis due to Non-Alcoholic Steatohepatitis (NASH) makes the need for a modern and convenient ascites treatment all the more important. We are also encouraged by the announcement from CMS in respect of proposed changes to the new technology add-on payment (NTAP) pathway for breakthrough devices, which we believe is a very promising development for the alfapump.”
     
    The POSEIDON study is a single arm, open-label, within subject crossover study of the alfapump in patients with recurrent or refractory ascites due to liver cirrhosis in centres across the United States and Canada. Sixty patients will be enrolled in the study cohort to enter the pre-implant observation period, allowing for up to 50 patients to be implanted with the alfapump for primary endpoint analysis. The study allows for up to a further 30 patients to be enrolled in a training cohort, to ensure centres are experienced with the alfapump before the study cohort is enrolled. An application for Investigational Testing Authorisation (ITA) has been submitted to Health Canada as well.

    “Thanks to the positive interactive review process, we received an unconditional IDE approval in just 30 days”, said Gijs Klarenbeek, CMO of Sequana Medical. “The FDA has provided us with invaluable advice on the design of the POSEIDON study. The final study design allows for a reduced number of study patients to be enrolled and a shorter follow-up time for primary endpoint analysis. We look forward to a continued collaboration with the FDA and are excited to start POSEIDON together with the investigators participating in this study.”
     
    Patients will enter into a three-month pre-implant observation period in which they will receive standard of care therapy, consisting of paracentesis, before the alfapump is implanted. Eligible patients will be implanted with the alfapump and monitored during a three-month stabilization period to adjust the settings of the alfapump as per patients’ needs. After this period of stabilization, a three-month post-implant observation period will begin. The primary effectiveness outcomes of the study include the proportion of patients with a 50 percent reduction in the overall average frequency of therapeutic paracentesis per month in the post-implant observation period (month three to month six after implantation) as compared to the pre-implant observation period and the per-patient ratio of post-implant to pre-implant with respect to average monthly number of therapeutic paracentesis. The primary safety endpoint is the rate of alfapump related re-interventions adjudicated by the Clinical Events Committee. Patients will be followed up for up to two years for analysis of secondary outcome measurements including safety (device and/or procedure-related adverse events), quality of life (assessed by general SF-36 as well as disease-specific Ascites-Q questionnaires), patients’ nutritional status, health economics and overall survival.
     
    About the alfapump in Recurrent or Refractory Ascites Due to Liver Cirrhosis
    Ascites, a key complication of liver cirrhosis, is the accumulation of ascitic fluid in the abdomen. Patients may accumulate as much as 10 to 15 litres of ascitic fluid within the abdomen every 15 days. Patients suffering from recurrent or refractory ascites have limited treatment options and often have severely impacted quality of life due to the severe swelling of the abdomen, resulting in pain, difficulty breathing, moving, sleeping and eating, severe nausea and constipation. Existing treatment options carry the risk of significant or life-threatening side effects, provide only short-term symptomatic relief or have very limited availability. The number of patients with refractory liver ascites is forecast to increase dramatically due to the growing prevalence of NASH (Non-alcoholic Steatohepatitis).
     
    Sequana Medical’s alfapump is a fully-implanted, programmable, wireless, CE-marked system that automatically pumps ascites from the peritoneal cavity into the bladder, where the body eliminates the ascites naturally through urination. The potential of the alfapump to address the unmet medical need in patients with recurrent or refractory ascites has been demonstrated in multiple clinical studies showing a significant reduction in the need for large volume paracentesis, which is paracentesis where at least five litres of fluid is removed (i.e., the current standard of care), and a significant improvement in patients’ quality of life.
     
    A feasibility study in North America in patients with refractory or recurrent ascites has been completed and results were presented at the AASLD (American Association for the Study of Liver Diseases) annual meetings in October 2017 and November 2018.
     
    Sequana Medical is a commercial stage medical device company focused on the development of treatments for the management of liver disease, heart failure, malignant ascites, and other fluid imbalance disorders. Sequana Medical's technology is based on its proprietary alfapump platform, which is applicable across multiple life-threatening disorders. The alfapump is being commercialized in Europe for the management of refractory ascites (chronic fluid build-up in the abdomen) due to liver cirrhosis and malignant ascites due to cancer. The number of patients with refractory liver ascites is forecast to increase dramatically due to the growing prevalence of NASH (Non-alcoholic Steatohepatitis).
     
    Over 700 alfapump systems have been implanted to date. The alfapump has been endorsed by key independent third parties in Europe and has been included in the EASL (European Association for the Study of the Liver) clinical practice guidelines for decompensated cirrhosis, the German treatment guidelines (DGVS) for complications of liver cirrhosis and the U.K. NICE interventional procedure guidance for treatment of refractory ascites caused by cirrhosis. In January 2019, the FDA granted Breakthrough Device designation to the alfapump for the treatment of recurrent or refractory liver ascites. The company expects to start POSEIDON, the North American pivotal study, in the second half of 2019 to support approval of the alfapump in recurrent or refractory liver ascites.
     
    Sequana Medical has leveraged its alfapump experience and is developing alfapump DSR (Direct Sodium Removal) to deliver a convenient and fully implanted system for DSR therapy, its proprietary approach for the management of volume overload in patients suffering from heart failure. DSR therapy involves the removal of sodium via diffusion from the body into the peritoneal cavity by administering a sodium-free solution (DSR infusate) into the abdomen. The DSR infusate and the extracted sodium are then removed using the alfapump and the body responds by eliminating the excess fluid via osmotic ultrafiltration (the movement of water, together with sodium, from the bloodstream to the peritoneal cavity) and/or urination. Volume overload in the body is a major clinical problem in heart failure, a condition that results in $13 billion of U.S. hospital admission costs annually. Data from the first-in-human single dose DSR proof-of-concept study presented at Heart Failure 2019 demonstrated that DSR can result in the removal of large quantities of sodium and fluid in a safe and tolerable manner.

    Sequana Medical is headquartered in Ghent, Belgium.
     
     
    Related Searches
    • quality
    • health
    • first
    • label
    Suggested For You
    TransEnterix Announces Japanese Regulatory Approval of the Senhance Surgical System TransEnterix Announces Japanese Regulatory Approval of the Senhance Surgical System
    TransEnterix Sells AutoLap Assets for $47M TransEnterix Sells AutoLap Assets for $47M
    AblaCare Raises €10 Million in Financing and Announces New CEO AblaCare Raises €10 Million in Financing and Announces New CEO
    FDA Shares Progress on Efforts to Increase Transparency in Medical Device Reporting FDA Shares Progress on Efforts to Increase Transparency in Medical Device Reporting
    FDA OKs MRI-Safe Cochlear Implant with Android Connectivity FDA OKs MRI-Safe Cochlear Implant with Android Connectivity
    A Breakthrough for the Nightmarish Effects of PTSD A Breakthrough for the Nightmarish Effects of PTSD
    FDA Clears Soliton FDA Clears Soliton's Acoustic Shockwave RAP Device for Tattoo Removal
    FDA Approves Device to Help Increase Access to More Lungs for Transplant FDA Approves Device to Help Increase Access to More Lungs for Transplant
    BioSig Technologies Expands its Engineering Team BioSig Technologies Expands its Engineering Team
    A New, Tailored Review Framework for Artificial Intelligence-Based Devices A New, Tailored Review Framework for Artificial Intelligence-Based Devices
    BioSig Announces Successful First-In-Human Use of PURE EP System BioSig Announces Successful First-In-Human Use of PURE EP System
    When Is It Time for a Quality Management System for Your Early Stage Firm? When Is It Time for a Quality Management System for Your Early Stage Firm?
    FDA to Modernize Mammography Services and Improve Their Quality FDA to Modernize Mammography Services and Improve Their Quality
    FDA Warns J&J and Sientra for Breast Implant Compliance Failure FDA Warns J&J and Sientra for Breast Implant Compliance Failure
    FDA to Closely Examine Surgical Stapler Risks FDA to Closely Examine Surgical Stapler Risks

    Related Breaking News

    • Digital Health | Software & IT
      15-Year Tele-Critical Care Collabration Yields Significant ICU Improvement Results

      15-Year Tele-Critical Care Collabration Yields Significant ICU Improvement Results

      Florida’s first eICU, powered by Philips telehealth technology, touts reduced mortality rates and hospital stays for the sickest patients.
      GlobeNewswire 12.11.19

    • 3D/Additive Manufacturing | Software & IT
      Prellis Biologics

      Prellis Biologics' New Tool Simplifies Complex Tissue Engineering

      TissueWorkshop generates complex 3D scaffolds that can be printed with any 3D printing system.
      Krause Taylor Associates 12.11.19

    • InspireMD

      InspireMD's CEO Steps Down

      New CEO Marvin Slosman, a life sciences industry veteran, joins InspireMD from Integra LifeSciences.
      GlobeNewswire 12.11.19


    • Celmatix Sues Research Partner 23andMe for $100M

      Celmatix Sues Research Partner 23andMe for $100M

      Celmatix claims breaches of the parties' agreement and tortious interference with efforts to raise capital.
      PR Newswire 12.11.19

    • FDA Cleared New Cochlear Osia 2 System

      FDA Cleared New Cochlear Osia 2 System

      The world’s first active osseointegrated steady-state implant.
      Cochlear 12.11.19

    • Neurological
      FDA Approves First Nasal Rescue Treatment for Frequent Seizure Activity

      FDA Approves First Nasal Rescue Treatment for Frequent Seizure Activity

      Aptar’s Unidose Liquid System can deliver a formulation in an emergency situation quickly and easily and be administered by a non-healthcare professional.
      Business Wire 12.10.19


    • Diagnostics
      Lens-Free Microendoscope Generates High Quality Images

      Lens-Free Microendoscope Generates High Quality Images

      It also doesn't require movement to focus on objects at different depths.
      Johns Hopkins University 12.10.19

    • Patient Monitoring | Software & IT
      Roche

      Roche's Blood Glucose Reading Smartphone App Gains CE Mark

      The app determines blood glucose ranges by taking photos with the smartphone camera without the need for a blood glucose meter.
      GlobeNewswire 12.10.19

    • FDA BDP Designation for the iLet Bionic Pancreas System

      FDA BDP Designation for the iLet Bionic Pancreas System

      The world’s first fully automated bionic pancreas.
      Beta Bionics 12.10.19


    • Diagnostics
      NeuMoDx Molecular and Sentinel Diagnostics Partner

      NeuMoDx Molecular and Sentinel Diagnostics Partner

      Work together to develop multiple new assays for the NeuMoDx Molecular Systems.
      NeuMoDx Molecular 12.10.19

    • Neural Analytics Enrolls First Patient With Its Next-Generation Lucid Robotic System

      Neural Analytics Enrolls First Patient With Its Next-Generation Lucid Robotic System

      The new IDE version of the technology is intended to improve performance and ease of use for the company’s robotic platform.
      Business Wire 12.10.19

    • Cardiovascular | Neurological
      Imperative Care Closes a Series C Financing of $85 Million for Stroke Treatments

      Imperative Care Closes a Series C Financing of $85 Million for Stroke Treatments

      The funds will support the commercial launch of the company’s portfolio.
      Imperative Care Inc. 12.10.19

    • Contract Manufacturing
      Medical Murray Holds Open House

      Medical Murray Holds Open House

      Event centered around new 35,000 square foot facility.
      Medical Murray 12.10.19

    • Cardiovascular
      FDA Grants Supplemental-PMA Approval to Impulse Dynamics

      FDA Grants Supplemental-PMA Approval to Impulse Dynamics' Next-Generation Optimizer Smart System

      Product offers a new therapy for heart failure patients with reduced ejection fraction.
      Businesswire 12.10.19

    • OmniGuide Holdings Expands Executive Team

      OmniGuide Holdings Expands Executive Team

      Company hires global marketing VP and managing director of Surgical Strategic Business Unit.
      Businesswire 12.10.19


    Breaking News
    • 15-Year Tele-Critical Care Collabration Yields Significant ICU Improvement Results
    • Prellis Biologics' New Tool Simplifies Complex Tissue Engineering
    • InspireMD's CEO Steps Down
    • Celmatix Sues Research Partner 23andMe for $100M
    • FDA Cleared New Cochlear Osia 2 System
    View Breaking News >
    CURRENT ISSUE

    November/December 2019

    • Adding Fabrication Capabilities: Additive Manufacturing for Production Parts
    • Delivering the Goods: The Evolving World of Combination Products
    • Anxious Undertones: The 2019 Year in Review
    • View More >
    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Deerland Obtains Certification from Australia’s Therapeutic Goods Administration
    OptiMSM Shown to Improve Hair & Nail Appearance and Condition
    DCC Acquires Contract Manufacturer Ion Laboratories
    Coatings World

    Latest Breaking News From Coatings World

    Beckers Group Announces Global Price Increase on Coil, Industrial Coatings
    Evonik, Wynca Celebrate Groundbreaking of New Fumed Silica Plant in Zhenjiang
    Personnel Changes in Corporate Communications, Government Relations at BASF
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    15-Year Tele-Critical Care Collabration Yields Significant ICU Improvement Results
    Prellis Biologics' New Tool Simplifies Complex Tissue Engineering
    InspireMD's CEO Steps Down
    Contract Pharma

    Latest Breaking News From Contract Pharma

    CatSci Expands Capabilities with Lab Expansion
    Smart Tags on Pills Set to Improve Supply Chain Security and Patient Adherence
    PCI Pharma Services Invests in Tredegar, UK Site
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Time Features 5 Best Beauty Inventions
    CES 2020 Preview - Innovation Award Honorees in Health & Wellness
    Star of E!'s Botched Gets Line Leaping Bunny Certified
    Happi

    Latest Breaking News From Happi

    Birchbox Partners with Buzzfeed
    Coty Strengthens Its Leadership
    Jennifer Garner Joins Virtue Labs
    Ink World

    Latest Breaking News From Ink World

    Smurfit Kappa, Wings for Aid Create Disaster Relief Packaging Solution
    ePac Flexible Packaging Expands into Asia Pacific Market
    United Carton Industries Company Invests in EFI Nozomi Corrugated Printer
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Luminer promotes Heather Bookman to prepress manager
    Materials Exchange launches to solve excess inventory issue
    Mark Andy joins forces with UPM Raflatac
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Simavita Set to License Sensor Technology in EU
    NDC Appoints President
    AATC Adds Two Scholarships
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    TriMed Closes Out FDA Warning Letter
    FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System
    OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    SEMI Releases Global Semiconductor Equipment Sales Forecast
    eMagin Corporation Announces Approximately $4.3 Million Order for Military Program
    CPI Supports Smart Food-labeling Project Set to Reduce Food Waste in 2020

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.